Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Purchased by Prospera Financial Services Inc

Prospera Financial Services Inc raised its holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 12.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 168,885 shares of the biopharmaceutical company’s stock after acquiring an additional 19,315 shares during the period. Prospera Financial Services Inc’s holdings in Puma Biotechnology were worth $431,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of PBYI. Los Angeles Capital Management LLC acquired a new position in shares of Puma Biotechnology during the 3rd quarter valued at about $627,000. Affinity Asset Advisors LLC acquired a new position in Puma Biotechnology in the 2nd quarter valued at about $815,000. SG Americas Securities LLC purchased a new stake in shares of Puma Biotechnology in the 1st quarter valued at approximately $57,000. Frazier Life Sciences Management L.P. increased its holdings in shares of Puma Biotechnology by 8.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock worth $9,984,000 after buying an additional 246,264 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC raised its position in shares of Puma Biotechnology by 127.7% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 77,081 shares of the biopharmaceutical company’s stock valued at $409,000 after buying an additional 43,229 shares during the period. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Stock Up 3.4 %

Puma Biotechnology stock opened at $3.00 on Monday. The company has a market capitalization of $147.27 million, a PE ratio of 6.25 and a beta of 1.09. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. Puma Biotechnology, Inc. has a fifty-two week low of $2.22 and a fifty-two week high of $7.73. The firm has a 50 day moving average price of $2.77 and a 200 day moving average price of $3.16.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The firm had revenue of $80.50 million for the quarter, compared to the consensus estimate of $71.32 million. During the same quarter in the previous year, the business earned $0.12 EPS. Research analysts expect that Puma Biotechnology, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on PBYI. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a research note on Wednesday, November 20th. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.